{
    "clinical_study": {
        "@rank": "19841", 
        "arm_group": [
            {
                "arm_group_label": "Lower-Risk Myelodysplastic Syndromes (LR MDS)", 
                "description": "Newly diagnosed lower risk MDS patients as determined by International Prognostic Scoring System (IPSS)."
            }, 
            {
                "arm_group_label": "Higher-Risk Myelodysplastic Syndromes (HR MDS)", 
                "description": "Newly diagnosed higher risk MDS patients as determined by International Prognostic Scoring System (IPSS)."
            }, 
            {
                "arm_group_label": "Acute Myeloid Leukemia (AML)", 
                "description": "Newly diagnosed AML patients (\u226555 years old, excluding patients with acute promyelocytic leukemia (APL)."
            }, 
            {
                "arm_group_label": "Unknown-Risk MDS", 
                "description": "Newly diagnosed unknown-risk MDS patients as determined by International Prognostic Scoring System (IPSS); defined as not having risk assigned due to unsuccessful cytogenetics after two bone marrow attempts."
            }
        ], 
        "biospec_descr": {
            "textblock": "Perform molecular and cellular correlative studies on blood/bone marrow and oral epithelial\n      cell samples."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of the Connect\u00ae MDS/AML Disease Registry is to provide unique insights into\n      treatment regimens and sequencing of these regimens as they relate to clinical outcomes of\n      patients with newly diagnosed MDS or AML in routine clinical practice and evaluate molecular\n      and cellular markers that may provide further prognostic classification and/or might be\n      predictive of therapy outcomes."
        }, 
        "brief_title": "Connect\u00ae MDS/AML Disease Registry", 
        "completion_date": {
            "#text": "December 2021", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Myelodysplastic Syndromes", 
            "Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This Disease Registry will collect data on patient characteristics, treatment patterns and\n      clinical outcomes.  The objective is to describe how newly diagnosed MDS or AML patients are\n      treated; and to build a knowledge base regarding the effectiveness and safety of front-line\n      and subsequent treatment regimens in both community and academic settings.  Enrolled\n      patients will receive treatment and evaluations for MDS or AML according to the standard of\n      care and routine clinical practice at each study site.  All treatments that patients receive\n      for MDS or AML will be recorded, including initial treatment and any subsequent therapy.\n      Data on treatment outcomes, including response rates as measured by the treating physician,\n      evidence of progression, survival, and patient-reported outcomes will be collected quarterly\n      on the electronic CRF."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must be able to provide written informed consent\n\n          -  Newly diagnosed (confirmed diagnosis within 60 days prior to enrollment), primary or\n             secondary Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)\n\n          -  Disease diagnosis confirmed by Central Eligibility Review\n\n          -  MDS patients of unknown-risk must have undergone two (2) bone marrow tests with\n             failed cytogenetics\n\n          -  AML patients must be at least 55 years of age at the time of informed consent\n             signature\n\n          -  MDS patients must be at least 18 years of age at the time of informed consent\n             signature\n\n          -  Patients must be willing and able to complete enrollment and follow-up HRQoL\n             instruments, for which patients must be proficient in either English or Spanish\n\n        Exclusion Criteria:\n\n          -  Diagnosis of acute promyelocytic leukemia (APL)\n\n          -  Diagnosis of MDS or AML rejected by Central Eligibility Review"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Approximately 1,500 patients across approximately 200 sites throughout the US will be\n        enrolled in the Connect\u00ae MDS and AML Registry.  Sites will include both community-based\n        and academic centers that are representative of where patients with MDS and AML are\n        diagnosed and treated.  To best capture the distribution of sites with regard to the\n        settings of where MDS and AML patients are typically treated in routine practice,\n        approximately 70-80% of the sites will be community hematology/oncology clinics and\n        approximately 20-30% will be academic-based institutions."
            }
        }, 
        "enrollment": {
            "#text": "1500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01688011", 
            "org_study_id": "Connect\u00ae MDS/AML Registry"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Myelodysplastic Syndromes", 
            "MDS", 
            "Acute Myeloid Leukemia", 
            "AML", 
            "Registry", 
            "Connect\u00ae"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boynton Beach", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33426"
                }, 
                "name": "University Cancer Institute"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "4", 
        "official_title": "Connect\u00ae MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry", 
        "overall_contact": {
            "email": "connectmdsaml-registry@celgene.com", 
            "last_name": "Melissa Nifenecker", 
            "phone": "908-219-0809"
        }, 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Oleg Zernovak, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Describe  demographics, baseline characteristics and  clinical outcomes of the patients with LR or HR MDS, MDS risk not determined, and AML.", 
                "measure": "Patient Demographics", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 years"
            }, 
            {
                "description": "Describe current and evolving patterns for diagnosis, treatment sequencing, routine clinical practice patterns and clinical outcome measures in patients with LR or HR MDS, MDS risk not determined, and AML", 
                "measure": "Diagnostic and Treatment Patterns", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 years"
            }, 
            {
                "description": "Describe the survival status, clinical response to treatment,  select laboratory results, occurrence of secondary primary malignancies,  deaths, select adverse events.", 
                "measure": "Safety and Effectiveness", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01688011"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Summarize patient reported outcomes (including e.g., Health-Related Quality of Life (HRQOL)) and economic outcomes, and their association with patient characteristics, treatment regimens, and clinical outcomes", 
                "measure": "Patient Reported Outcome", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 years"
            }, 
            {
                "description": "Perform molecular and cellular correlative studies on blood/bone marrow and oral epithelial cell samples.", 
                "measure": "Correlative Studies", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 years"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}